Aspirin versus rivaroxaban in postoperative bleeding after total knee arthroplasty: a retrospective case-matched study

Eur J Orthop Surg Traumatol. 2019 May;29(4):877-881. doi: 10.1007/s00590-019-02365-y. Epub 2019 Jan 9.

Abstract

Background: Venous thromboembolic disease (VTE) is a complication not uncommon following total knee arthroplasty. Postoperative bleeding-related complications are a concern in many guidelines. The authors aimed to compare the amount of postoperative drainage from closed suction drainage, transfusion rate, and postoperative complications between aspirin and rivaroxaban as VTE prophylaxes after total knee arthroplasty.

Methods: This study was a retrospective case-matched study of 155 patients. The data were collected between 2008 and 2015 from patients who had total knee arthroplasty using aspirin or rivaroxaban as the VTE prophylaxis. Seventy-nine patients received aspirin, and 76 patients received rivaroxaban. A single surgeon operated on all patients with the same surgical technique and patient care protocol.

Results: The total closed suction drainage outputs at 48 h were not significantly different between the aspirin and rivaroxaban groups (p = 0.10). Eighteen percent of patients in the aspirin group and 25% of patients in the rivaroxaban group received blood transfusions (p = 0.37). There were no bleeding-related complications or VTE in either group.

Conclusions: Aspirin and rivaroxaban were effective and safe as VTE chemoprophylaxis in total knee arthroplasty.

Keywords: Aspirin; Rivaroxaban; Total knee replacement; VTE.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Arthroplasty, Replacement, Knee*
  • Aspirin / therapeutic use*
  • Blood Transfusion / statistics & numerical data
  • Chemoprevention
  • Drainage*
  • Factor Xa Inhibitors / therapeutic use
  • Female
  • Humans
  • Male
  • Platelet Aggregation Inhibitors / therapeutic use
  • Postoperative Hemorrhage / therapy*
  • Retrospective Studies
  • Rivaroxaban / therapeutic use*
  • Venous Thromboembolism / prevention & control*

Substances

  • Factor Xa Inhibitors
  • Platelet Aggregation Inhibitors
  • Rivaroxaban
  • Aspirin